BIOINVENT
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR:registered:, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug d... iscovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers. BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others. BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.
BIOINVENT
Social Links:
Industry:
Biotechnology Health Care Manufacturing Pharmaceutical Product Research
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.bioinvent.se
Total Employee:
11+
Status:
Active
Contact:
(462) 868-550_
Email Addresses:
[email protected]
Total Funding:
2 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Font Awesome Microsoft Exchange Online Office 365 Mail Google Maps JsDelivr
Similar Organizations
Actient Holdings
Actient is a private urology specialty therapeutics company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Berlin Chemie
Berlin Chemie is an international pharmaceutical research company specializing the development and distribution of new pharma products.
Bharat Serums and Vaccines
Bharat Serums and Vaccines develops biopharmaceutical products for patient health improvement.
Biosearch
Biosearch is a state-of-the-art testing laboratory company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Janssen
Janssen is the pharmaceutical arm of Johnson & Johnson.
Medinfar
Medinfar is a Portuguese pharmaceutical company.
MSD
MSD is an research-based healthcare company.
Smartfish AS
Smartfish is a Norwegian, research-based company.
The Stevanato Group
Stevanato Group S.p.A. manufactures packaging containers from glass tubing for the pharmaceutical industry worldwide.
Current Advisors List
Current Employees Featured
Stock Details
Newest Events participated
Participated in BioProcess International European Summit 2017
on 2017-04-25 as exhibitor
Participated in Viral Safety 2017
on 2017-04-25 as exhibitor
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-18 | BioInvent Appoints Experienced Industry Leader Marie Moores as Chief Operating Officer |
Official Site Inspections
http://www.bioinvent.se
- Host name: ec2-52-17-142-199.eu-west-1.compute.amazonaws.com
- IP address: 52.17.142.199
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "BioInvent"
Bioinvent - Wikipedia
BioInvent International is a Swedish clinical-stage biotech company that discovers and develops novel and first-in-class immunomodulatory antibodies for cancer therapy. The company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generatingnew drug candidates to fuel the Company’s own broad clinical development pipeline or for additional licensing and partnering. Currently, the company …See details»
About Us | BioInvent
BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology and antibody biology, BioInvent generates innovative immuno-oncology drug candidates. Immuno-oncology drugs constitute one of the main medical breakthroughs of the 21st century.See details»
Our History - BioInvent
BioInvent has a strong deal-making track record, and has ongoing collaborations with companies such as CASI, Merck, Daiichi and Mitsubishi Tanabe. Broad clinical pipeline BioInvent is broadening and developing an exciting pipeline of …See details»
Board of Directors - BioInvent
Chairman of the Board since 2018. Member of the Remuneration Committee and the Audit Committee. MBA, CPA. He served as a Board Member in BioInvent between 2016–2017. He was CFO and member of the board of Crucell NV from 1998 to 2011 and has held senior executive positions at Royal Boskalis N.V., GE Capital and Continental Can Company. Born 1958.See details»
Bioinvent International AB Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Bioinvent International AB of Lund, Skåne. Get the latest business insights from Dun & Bradstreet.See details»
BioInvent International AB - A Company At Ideon
BioInvent International AB, listed on the OMX Nordic Exchange Stockholm (BINV), is a research-based pharmaceutical company focused on the development and development of antibody drugs. Today, the company operates innovative drug projects in …See details»
BioInvent - Crunchbase Company Profile & Funding
BioInvent may be growing as indicated by a reported revenue growth of 28% over five years, which is a strong indicator of the company's financial performance. Additionally, BioInvent International shareholders have experienced a 15% …See details»
BioInvent announces 2024 strategic priorities and anticipated ...
Sep 30, 2023 Lund, Sweden – January 04, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today highlighted the Company’s strategic priorities and anticipated milestones for 2024.See details»
BioInvent’s CEO on the benefits of a diversified portfolio
Sep 28, 2021 BioInvent‘s main focus is to identify and develop novel, first-in-class immuno-modulatory antibodies for cancer treatment. In other words, drugs with completely new and unique mechanisms of action with the ability to strengthen, stimulate or activate the body’s immune system so that cancer diseases can be combated.See details»
BioInvent strengthens the organisation with COO - BioStock
Feb 1, 2022 Swedish biotech BioInvent strengthened its pipeline of cancer treatments in 2021, entering the new year with four candidates in clinical phase, which is soon to be expanded with a fifth. Given the higher pace and increased regulatory work this entails, the company has now strengthened the organisation with Marie Moores as Chief Operating Officer.See details»
| BioInvent
Dec 31, 2022 BioInvent has a long history and a strong position in the generation and development of antibody drugs. The foundation of the company is expertise in immunology, cancer biology and antibody biology. Today, BioInvent is a company with multiple clinical programs ongoing.See details»
BioInvent International AB - Lund, Sweden - bionity.com
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.See details»
BioInvent appoints Ashley Robinson as SVP Strategy ... - placera.se
5 days ago Lund, Sweden and Boston, US – December 3, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the appointment of Ashley Robinson as SVP Strategy & Finance, effective …See details»
Lund - BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just …See details»
BioInvent Company Profile - Office Locations, Competitors, …
Oct 29, 2024 BioInvent has 5 employees at their 1 location and kr71.46 m in annual revenue in FY 2023. See insights on BioInvent including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Working at BioInvent
BioInvent Manufacturing, the contract manufacturing business unit of BioInvent International AB, has a proven track record for clients and partners since 1988. ... As a relatively small organization, we have an informal and flexible work environment, providing numerous opportunities for professional and personal development. Our ScienceSee details»
BioInvent anticipates strong influx of clinical data - BioStock
Oct 31, 2024 BioInvent has also reported significant progress during Q3 across multiple other clinical trials. Preliminary data from the phase IIa dose-expansion study of BI-1808 as a monotherapy in patients with cutaneous T-cell lymphoma (CTCL) showed encouraging results, with three partial responses and one case of stable disease among four evaluable patients.See details»
BioInvent anticipates a continued data-rich 2024 - BioStock
Sep 2, 2024 With the current burn rate, BioInvent maintains a strong financial foundation, ensuring the company is well-equipped to sustain its operations through the second half of 2024 and beyond. Taking a closer look at the company’s partnerships, one notable collaboration is the agreement with CASI Pharmaceuticals , signed in 2020 with an upfront payment of USD 12 …See details»
BioInvent: Significant Advances in Cancer Treatment
May 31, 2024 BioInvent is also testing a drug called BI-1206 in combination with other treatments (rituximab and pembrolizumab) for non-Hodgkin’s lymphoma, a type of cancer. BI-1206 is designed to target a protein called FcγRIIB, which is often overproduced in aggressive forms of this cancer.See details»
Manufacturing | BioInvent
BioInvent offers a range of cell line development options that include a royalty free GS knocked CHO K1 cell line. BioInvent is conveniently located, in the university town of Lund Sweden, just 40 minutes from Copenhagen International Airport. The facility is licensed by the Swedish Medical Products Agency and is inspected on a regular basis ...See details»